Qualigen therapeutics initiates good laboratory practice (glp) toxicology studies on qn-302

Carlsbad, calif., jan. 24, 2023 (globe newswire) -- qualigen therapeutics, inc. (“qualigen” or “the company,” nasdaq: qlgn), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for orphan drug designation, while also commercializing diagnostics, today announces the initiation of good laboratory practice (glp) toxicology studies of its lead oncology program, qn-302, a g4-selective transcription inhibitor currently in development for the treatment of g4 (g-quadruplex) expressing solid tumors, including pancreatic cancer.
QLGN Ratings Summary
QLGN Quant Ranking